GlassScriptPhysician profile
Amanda L Hunter
NPI 1700242005
$3,334.74
in general payments reported to CMS, 2019-2025
27 companies · $1,816 in 2025
The $1,816 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $333 · 2022: $175 · 2023: $538 · 2024: $472 · 2025: $1,816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,826.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $699.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $400.56 | 2021-2025 | |
| Dexcom, INC. | $338.86 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.87 | 2021-2025 | Jardiance |
| Abbott Laboratories | $232.13 | 2022-2025 | Freestyle Libre |
| Amgen INC. | $195.45 | 2022-2025 | Evenity, Prolia, Tepezza |
| Radius Health, INC. | $131.92 | 2023-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $125.14 | 2023-2025 | |
| Cequr Corporation | $109.03 | 2023-2024 | Cequr Simplicity |
| Antares Pharma, INC. | $88.45 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Ascendis Pharma Endocrinology INC | $84.16 | 2024-2025 | Yorvipath |
| Medtronic, INC. | $80.80 | 2023-2025 | Minimed 780g |
| Lilly USA, LLC | $79.69 | 2024-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $79.65 | 2021-2023 | Farxiga |
| Tandem Diabetes Care, INC. | $67.47 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $62.39 | 2022-2023 | Omnipod |
| Novartis Pharmaceuticals Corporation | $60.71 | 2023-2024 | |
| Beta Bionics, INC. | $54.03 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbvie INC. | $39.81 | 2025 | |
| Neurocrine Biosciences, INC. | $27.14 | 2025 | |
| Horizon Therapeutics Plc | $23.43 | 2023 | Tepezza |
| Integra Lifesciences Corporation | $20.15 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $20.03 | 2025 | Evkeeza |
| Sequel Med Tech, LLC | $18.91 | 2025 | Twiist |
| Ibsa Pharma INC. | $17.07 | 2025 | Tirosint, Licart, Flector |
| Kyowa Kirin, INC. | $16.50 | 2025 | |
| Amneal Pharmaceuticals LLC | $13.88 | 2025 | Unithroid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.